Ramsay-Hunt Syndrome

01Pathophysiology

Ramsay Hunt Syndrome results from the reactivation of varicella-zoster virus (VZV) that has remained dormant in the geniculate ganglion following a primary varicella infection, often decades earlier. The geniculate ganglion is the sensory ganglion of the facial nerve (CN VII), located within the temporal bone at the junction where the facial nerve makes its first sharp turn (the "genu" or knee of CN VII).

When the virus reactivates, it travels anterogradely along sensory fibers of CN VII. The nervus intermedius, the sensory root of CN VII, provides innervation to portions of the auricle, external auditory canal, and a small region of the tympanic membrane. This is why vesicles erupt in these anatomical distributions rather than along a typical dermatome. The viral inflammation and edema within the narrow fallopian canal (the bony canal housing the facial nerve through the temporal bone) directly compresses CN VII motor fibers, producing an ipsilateral lower motor neuron facial palsy that is clinically indistinguishable in pattern from Bell palsy.

Because the geniculate ganglion sits in close anatomical proximity to the vestibulocochlear nerve (CN VIII), viral spread or inflammatory edema can affect this neighboring structure. This explains why patients may develop sensorineural hearing loss, vertigo, nausea, and tinnitus, features that are not seen in isolated Bell palsy and serve as distinguishing findings on exam vignettes.

The prognosis of Ramsay Hunt Syndrome is notably worse than Bell palsy. Only about 50-70% of patients with Ramsay Hunt Syndrome achieve complete facial nerve recovery, compared to approximately 85-90% for Bell palsy. This is because the direct viral cytopathic effect on the nerve causes more severe axonal damage than the presumed immune-mediated inflammation of Bell palsy.

02Classification and Clinical Manifestation

Classic Triad

Associated Features by Cranial Nerve Involvement

Staging by Severity

A critical teaching point: "Zoster sine herpete" is a recognized variant where the patient develops facial paralysis and otalgia without visible vesicles. This is an extremely high-yield exam trap because the absence of rash may lead students to diagnose Bell palsy instead. PCR testing of saliva or middle ear fluid can confirm VZV reactivation in these cases.

03Diagnostic Workup

Summary Table

Ramsay Hunt Syndrome is fundamentally a clinical diagnosis. When a patient presents with the classic triad of otalgia, ipsilateral facial paralysis, and vesicular eruption on the ear, no further testing is strictly required to establish the diagnosis. The vignette itself is the diagnostic test, and the exam is testing whether you can recognize this pattern.

However, when the presentation is atypical or the rash has not yet appeared, PCR of vesicle fluid (or saliva if vesicles are absent) is the most accurate confirmatory test. PCR detects VZV DNA with high sensitivity and can distinguish VZV from HSV, which is relevant because herpes simplex can occasionally produce a similar clinical picture.

Tzanck smear is a classic exam topic. Scraping the base of a vesicle reveals multinucleated giant cells, but this test cannot differentiate between VZV and HSV. It is rapid and inexpensive, making it a reasonable bedside test, but it is neither sensitive nor pathogen-distinguishing. Test-writers love asking what Tzanck smear shows and whether it can confirm VZV over HSV (it cannot).

MRI with gadolinium may demonstrate enhancement of the facial nerve at the level of the geniculate ganglion and within the fallopian canal. This is not routinely needed for diagnosis but may appear in vignettes asking about imaging findings or when the diagnosis is uncertain.

Audiometry should be obtained in all patients to document baseline hearing and to detect sensorineural hearing loss. This also has prognostic value.

04Management and Treatment

Summary Table

The cornerstone of treatment is combined antiviral therapy plus corticosteroids, and the critical teaching point is that both must be started within 72 hours of symptom onset for optimal outcomes. This time window appears frequently in exam questions.

Valacyclovir is generally preferred over acyclovir in the outpatient setting because its superior oral bioavailability allows less frequent dosing (three times daily versus five times daily), improving adherence. The antiviral agent works by inhibiting viral DNA polymerase after being phosphorylated by VZV thymidine kinase, limiting ongoing viral replication and neural destruction.

Corticosteroids are added to reduce the inflammatory edema within the rigid fallopian canal. Because the canal is a confined bony space, even modest swelling creates compression injury to the facial nerve. Prednisone is typically started at 1 mg/kg/day (maximum 60 mg/day) for 5-7 days, followed by a gradual taper over 1-2 weeks. There is ongoing debate about corticosteroid benefit in isolation, but the combination of antivirals plus corticosteroids has shown improved rates of facial nerve recovery compared to antivirals alone.

Eye care is a "next best step" concept that test-writers frequently include. Because facial nerve palsy prevents complete eyelid closure, the cornea is at risk for exposure keratopathy and even corneal ulceration. Every patient with facial paralysis should receive aggressive eye protection: artificial tears during the day, lubricating ointment at night, and taping the eyelid or using a moisture chamber during sleep.

For immunocompromised patients, intravenous acyclovir (10 mg/kg every 8 hours) is indicated due to the risk of disseminated zoster. Renal dosing adjustments are necessary for both acyclovir and valacyclovir, as these drugs are nephrotoxic and can cause crystalline nephropathy, particularly in dehydrated patients or those with pre-existing renal impairment.

Postherpetic neuralgia (persistent pain after rash resolution) may require long-term management with gabapentin (starting at 300 mg/day, titrated to 1800-3600 mg/day in divided doses), pregabalin, tricyclic antidepressants (amitriptyline 25-75 mg at bedtime), or topical lidocaine patches.

05Differential Diagnosis and Distractors

06Traps and High-Yield Pearls

The most common way students get questions on Ramsay Hunt Syndrome wrong is by defaulting to a Bell palsy diagnosis whenever they see facial nerve palsy. Bell palsy is by far the more common condition, and because it is an "idiopathic" diagnosis of exclusion, students often anchor to it too quickly. The critical discriminator that test-writers embed in the stem is the presence of vesicles on or near the ear and/or CN VIII symptoms (hearing loss, vertigo). If either of these features appears in the vignette, Bell palsy is the wrong answer.

A second major trap involves zoster sine herpete, the variant where the vesicular rash is absent or has not yet appeared at the time of presentation. In these vignettes, the patient has facial paralysis, severe otalgia, and possibly auditory or vestibular symptoms, but no visible rash. The question may ask for the next best diagnostic step, and the answer is VZV PCR of saliva or vesicle fluid (if vesicles later appear).

A third high-yield concept is the timing of treatment. Antivirals and corticosteroids must be initiated within 72 hours to offer meaningful benefit. Vignettes testing management may present a patient who is 5 days into symptoms and ask whether antivirals are still indicated. The evidence for benefit beyond 72 hours is weak, but most guidelines still recommend treatment for immunocompromised patients regardless of timing.

Finally, never forget the eye protection question. A patient with facial palsy who cannot close the eyelid is at risk for corneal damage. If the question asks, "What is the most important supportive measure?" the answer involves protecting the cornea with artificial tears and nighttime taping, not simply prescribing antivirals.

The core competency being tested is pattern recognition: distinguishing Ramsay Hunt Syndrome from Bell palsy through the presence of vesicular eruption and CN VIII involvement, initiating combined antiviral-corticosteroid therapy within the treatment window, and understanding the anatomical basis for each clinical feature.